Exchange: NASDAQ·Updated 07:30 PM EDT

ALNY News

News
all
press releases
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
Zacks
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
Zacks
More News
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
Zacks
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
Zacks
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
Zacks
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Zacks
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
Zacks
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
Zacks
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.
Zacks
Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.0% on an annualized basis producing an average annual return of 14.01%. Currently, Alnylam Pharmaceuticals has a marketread more...
Benzinga
AMVUTTRA (vutrisiran) Play by Play Initiative Highlights Former Athletes Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA (vutrisiran) Play by Play, a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM...
Business Wire

Advertisement|Remove ads.